02 May 2021>: Clinical Research
Parameters Indicating Development of Influenza-Associated Acute Necrotizing Encephalopathy: Experiences from a Single Center
Suyun Li 1AE* , Dandan Hu 2AE* , Peiqing Li 1AE* , Weiqiang Xiao 3AE* , Huixian Li 4ACE* , Guangming Liu 1C , Yongling Song 1C , Shuyao Ning 2C , Qiuyan Peng 1F , Danyang Zhao 5F , Minxiong Situ 5F , Wanqi Li 1B , Peiqun Wu 1B , Jipeng Zheng 1B , Yueting Liu 1B , Lin Hu 1B , Pengfei Wang 1B , Zhengbin Hu 1B , Wencheng Ma 1D , Jun Shen 1D , Sida Yang 2A*DOI: 10.12659/MSM.930688
Med Sci Monit 2021; 27:e930688
Table 1 Demographic and clinical characteristics.
Characteristics, n (%) or as shown | FA, n=4 | FS, n=8 | IAE, n=14 | IANE, n=5 |
---|---|---|---|---|
Gender, Male | 3 (75) | 3 (37.5) | 10 (71.4) | 2 (40) |
Age, years, mean (SD) | 5.2 (3.6) | 4.1 (2.4) | 5.4 (3.3) | 3.6 (1.9) |
Weight, kg, median (IQR) | 15.35 (11.75, 21.85) | 15.5 (12, 18.35) | 18.5 (13.5, 26) | 15 (13, 17) |
Onset date | ||||
January | 4 (100) | 5 (62.5) | 7 (50) | 3 (60) |
December | 0 (0) | 1 (12.5) | 4 (28.57) | 1 (20) |
Others* | 0 (0) | 2 (25) | 3 (21.43) | 1 (20) |
Fever, day, median (IQR) | 4.5 (4, 9.5) | 2 (1, 2) | 1 (1, 3)* | 3 (1, 4) |
Temperature, °C, median (IQR) | 39 (39, 39.5) | 39.5 (39, 40) | 39 (39, 39.25) | 39 (39, 39) |
Seizure | ||||
No | 4 (100) | 0 (0)* | 3 (21.4) | 0 (0),* |
1–2 | 0 (0) | 8 (100) | 4 (28.6) | 1 (20) |
≥3 | 0 (0) | 0 (0) | 7 (50) | 4 (80) |
Cough, yes | 4 (100) | 7 (87.5) | 9 (64.3) | 3 (60) |
Vomiting, yes | 1 (25) | 0 (0) | 6 (42.9) | 2 (40) |
Sleepiness, yes | 2 (50) | 2 (25) | 4 (28.6) | 1 (20) |
Somnolence, yes | 1 (25) | 1 (12.5) | 1 (7.1) | 1 (20) |
ADOC, yes | 0 (0) | 0 (0) | 0 (0) | 3 (60) |
Alalia, yes | 0 (0) | 0 (0) | 3 (21.4) | 1 (20) |
Gibberish, yes | 0 (0) | 0 (0) | 3 (21.4) | 0 (0) |
Babinski’s sign, yes | 0 (0) | 0 (0) | 0 (0) | 3 (60) |
Tachycardia, yes | 3 (75) | 0 (0) | 1 (7.1) | 1 (20) |
Etiology | ||||
Influenza A | 4 (100) | 8 (100) | 11 (73.3) | 4 (80) |
Influenza B | 0 (0) | 0 (0) | 4 (26.7) | 1 (20) |
Treatment | ||||
Oseltamivir/peramivir | 4 (100) | 7 (87.5) | 12 (85.7) | 5 (100) |
IVIG | 2 (50) | 0 (0) | 5 (35.7) | 5 (100) |
Glucocorticoids | 2 (50) | 0 (0) | 3 (21.4) | 4 (80) |
Antibiotics | 1 (25) | 2 (25) | 2 (14.3) | 3 (60) |
Tracheal intubation ventilator ventilation | 0 (0) | 0 (0) | 0 (0) | 2 (40) |
Outcome | ||||
Non-survivor/sequela | 0 (0) | 0 (0) | 0 (0) | 4 (80),** |
* FA group were selected as controls and -value ** FS group were selected as controls and -value *** IAE group were selected as controls and -value |